JPRN-jRCT2080221261未知3 期
Confirmatory study of TRK-820 Soft Capsules-Intractable Pruritus in Patients with Chronic Liver Disease
适应症
试验速览
- 阶段
- 3 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Chronic Liver Disease
- •It can be confirmed that the treatment of pruritus with antihistamines or antiallergics has not been adequately effective in such patients.
排除标准
- •Malignant tumors except for early-stage hepatocellular carcinoma
- •Allergy to opioid drugs
研究者
相似试验
未知
3 期
ong-term Administration Study of TRK-820 Soft CapsulesIntractable Pruritus in Patients With Chronic Liver DiseaseJPRN-jRCT2080221262Toray Industries,Inc.
已完成
2 期
Phase II Study of TRK-820 Soft Capsules - Intractable Pruritus in Patients With Chronic Liver Disease -Pruritus With Chronic Liver DiseaseNCT00638495Toray Industries, Inc120
未知
1 期
Pharmacokinetic study of TRK-820 -Pharmacokinetic study among TRK-820 tablets and TRK-820 soft capsules.Healthy Japanese MaleJPRN-jRCT1080221878Toray Industries,Inc.8
未知
3 期
Open-label study of TAK-875Diabetes mellitusJPRN-jRCT2080221565TAKEDA PHARMACEUTICAL COMPANY LTD.
进行中（未招募）
1 期
Bayer 20810 - A Phase 1/2 Study of the TRK Inhibitor Selitrectinib (BAY2731954) in Adult and Pediatric Subjects with Previously Treated NTRK Fusion CancersTRK fusion cancers previously treated with a TRK inhibitorMedDRA version: 21.0Level: LLTClassification code 10049516Term: Malignant tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10007958Term: Central nervous system neoplasmSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-004246-20-BEBayer Consumer Care AG186